FR3007653A3 - USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS - Google Patents

USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS Download PDF

Info

Publication number
FR3007653A3
FR3007653A3 FR1356165A FR1356165A FR3007653A3 FR 3007653 A3 FR3007653 A3 FR 3007653A3 FR 1356165 A FR1356165 A FR 1356165A FR 1356165 A FR1356165 A FR 1356165A FR 3007653 A3 FR3007653 A3 FR 3007653A3
Authority
FR
France
Prior art keywords
noble gas
volume
treatment
medicament according
ischemas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1356165A
Other languages
French (fr)
Inventor
Ira Katz
Jan Pype
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Air Liquide SA
Priority to FR1356165A priority Critical patent/FR3007653A3/en
Publication of FR3007653A3 publication Critical patent/FR3007653A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/025—Helium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0258—Krypton (KR)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0291—Xenon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un médicament gazeux contenant un gaz noble pour une utilisation dans le traitement d'une lésion d'ischémie-reperfusion affectant l'intestin d'un patient, qu'il soit un être humain ou un animal. Le gaz noble est choisi parmi le xénon, l'argon, le néon, le krypton et l'hélium. La teneur en gaz noble dans le médicament gazeux est d'au moins 5% en volume.A gaseous drug containing a noble gas for use in the treatment of an ischemia-reperfusion injury affecting the intestine of a patient, whether a human being or an animal. The noble gas is selected from xenon, argon, neon, krypton and helium. The noble gas content in the gaseous drug is at least 5% by volume.

Description

L'invention porte sur un médicament gazeux contenant un gaz noble pour une utilisation dans le traitement d'une lésion d'ischémie-reperfusion affectant l'intestin d'un patient, qu'il soit un être humain ou un animal.A gaseous drug containing a noble gas for use in the treatment of an ischemia-reperfusion injury affecting the intestine of a patient, whether a human being or an animal.

Les gaz nobles, tel qu'argon et xénon, sont utilisés à différentes fins, notamment pour le pré-conditionnement, le maintien et la transplantation d'organes, en cas de greffe d' organes. Ils permettent en effet de préserver les organes à transplanter en réduisant les lésions d'ischémie-reperfusion qui peuvent s'y produire.Noble gases, such as argon and xenon, are used for a variety of purposes, including pre-conditioning, organ preservation and transplantation, in the case of organ transplantation. They make it possible to preserve the organs to transplant by reducing the ischemia-reperfusion injury that can occur.

Les lésions d'ischémie-reperfusion de l'intestin engendrent une mortalité élevée du fait d'interruptions non désirées des flux sanguins qui irriguent normalement l'intestin. Ceci peut se produire notamment lors d'une chirurgie d'un anévrisme aortique abdominal, d'un bipasse cardio-pulmonaire, d'une nécrose néonatale, d'une greffe intestinale...The ischemia-reperfusion injury of the intestine results in high mortality due to unwanted interruptions of blood flow that normally irrigates the intestine. This can occur especially during surgery of an abdominal aortic aneurysm, a cardiopulmonary bypass, a neonatal necrosis, an intestinal transplant ...

Différentes solutions curatives ou préventives ont été proposées pour lutter contre les lésions d'ischémie-reperfusion intestinales comme par exmeple le pré-conditionnement ischémique par exposition des tissus à de brèves périodes ischémiques permettant de les protéger des effets néfastes des ischémies-reperfusions prolongées ; ou l'usage d'antioxydants...Various curative or preventive solutions have been proposed to fight intestinal ischemia-reperfusion injury, such as ischemic pre-conditioning by exposing tissues to brief ischemic periods to protect them from the harmful effects of prolonged ischemia-reperfusion; or the use of antioxidants ...

Toutefois, aucune de ces solutions ne s'est avérée réellement efficace comme rappelé par le document de Mallick et al., 2004, Digestive Disorders and Sciences, 49, 1359-1377. Le problème qui se pose est dès lors de pouvoir protéger efficacement l'intestin contre les lésions d'ischémie-reperfusion.However, none of these solutions has been found to be truly effective as recalled by Mallick et al., 2004, Digestive Disorders and Sciences, 49, 1359-1377. The problem is therefore to be able to effectively protect the intestine against ischemia-reperfusion injury.

La solution de l'invention est un médicament gazeux contenant un gaz noble pour une utilisation dans le traitement d'une lésion d'ischémie-reperfusion affectant l'intestin chez un patient, c'est-à-dire chez un être humain ou un animal. Selon le cas, le médicament gazeux de l'invention peut comprendre l'une ou plusieurs des caractéristiques techniques suivantes : - le patient est un être humain, en particulier un homme ou une femme, y compris les enfants. - le gaz noble est choisi parmi le xénon, l'argon, le néon, le krypton et l'hélium. - le gaz noble est choisi préférentiellement parmi le xénon et l'argon. - il est administré par inhalation. - il est administré par insufflation dans l'abdomen. - il contient en outre au moins 21% d'oxygène, en particulier lorsqu'il est administré par inhalation. - la teneur en gaz noble est d'au moins 5% en volume, de préférence d'au moins 15% en volume. - la teneur en gaz noble est d'au moins 25% en volume, de préférence d'au moins 30% en volume. - la teneur en gaz noble est d'au moins 40% en volume, de préférence d'au moins 60% en volume. - la teneur en gaz noble est d'au moins 50% en volume. - le médicament est conditionné dans une bouteille de gaz sous pression.The solution of the invention is a gaseous drug containing a noble gas for use in the treatment of an ischemia-reperfusion injury affecting the intestine in a patient, i.e., a human or a human being. animal. Depending on the case, the gaseous drug of the invention may comprise one or more of the following technical characteristics: the patient is a human being, in particular a man or a woman, including children. the noble gas is chosen from xenon, argon, neon, krypton and helium. the noble gas is preferably chosen from xenon and argon. - it is administered by inhalation. - it is administered by insufflation in the abdomen. it also contains at least 21% oxygen, in particular when it is administered by inhalation. the noble gas content is at least 5% by volume, preferably at least 15% by volume. the noble gas content is at least 25% by volume, preferably at least 30% by volume. the noble gas content is at least 40% by volume, preferably at least 60% by volume. the noble gas content is at least 50% by volume. - the drug is packaged in a pressurized gas bottle.

L'administration du médicament gazeux de l'invention se fait au moyen d'un dispositif spécifique, tel un ventilateur d'abdomen équipé de tuyauteries adaptées, ou alors au moyen d'une interface patient, tel un masque respiratoire, une canule nasale ou une sonde trachéale lorsque le gaz est inhalé par le patient et donc administré via les poumons.The administration of the gaseous medicament of the invention is carried out by means of a specific device, such as an abdomen ventilator equipped with suitable pipes, or else by means of a patient interface, such as a respiratory mask, a nasal cannula or a tracheal tube when the gas is inhaled by the patient and thus administered via the lungs.

La durée d'administration, la teneur en gaz noble, la fréquence d'administration... sont déterminées au cas par cas par le personnel médical, en particulier par le médecin, en fonction de l'état de santé de chaque patient.The duration of administration, the noble gas content, the frequency of administration, etc. are determined on a case-by-case basis by the medical staff, in particular the doctor, according to the state of health of each patient.

Claims (7)

REVENDICATIONS1. Médicament gazeux contenant un gaz noble pour une utilisation dans le traitement d'une lésion d'ischémie-reperfusion affectant l'intestin chez un être humain ou un animal.REVENDICATIONS1. Gaseous drug containing a noble gas for use in the treatment of an ischemia-reperfusion injury affecting the intestine in a human or animal. 2. Médicament selon la revendication précédente, caractérisé en ce que le gaz noble est choisi parmi le xénon, l'argon, le néon, le krypton et l'hélium.2. Medicament according to the preceding claim, characterized in that the noble gas is selected from xenon, argon, neon, krypton and helium. 3. Médicament selon l'une des revendications 1 ou 2, caractérisé en ce qu'il contient en outre au moins 21% d'oxygène.3. Medicament according to one of claims 1 or 2, characterized in that it further contains at least 21% oxygen. 4. Médicament selon l'une des revendications précédentes, caractérisé en ce que l'être humain est un homme ou une femme. 154. Medicament according to one of the preceding claims, characterized in that the human being is a man or a woman. 15 5. Médicament selon la revendication précédente, caractérisé en ce que la teneur en gaz noble est d'au moins 5% en volume, de préférence d'au moins 25% en volume.5. Medicament according to the preceding claim, characterized in that the content of noble gas is at least 5% by volume, preferably at least 25% by volume. 6. Médicament selon la revendication précédente, caractérisé en ce que la teneur 20 en gaz noble est d'au moins 40% en volume, de préférence d'au moins 60% en volume.6. Medicament according to the preceding claim, characterized in that the content of noble gas is at least 40% by volume, preferably at least 60% by volume. 7. Médicament selon la revendication précédente, caractérisé en ce que le gaz noble est l'argon ou le xénon.7. Medicament according to the preceding claim, characterized in that the noble gas is argon or xenon.
FR1356165A 2013-06-27 2013-06-27 USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS Pending FR3007653A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1356165A FR3007653A3 (en) 2013-06-27 2013-06-27 USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1356165A FR3007653A3 (en) 2013-06-27 2013-06-27 USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS

Publications (1)

Publication Number Publication Date
FR3007653A3 true FR3007653A3 (en) 2015-01-02

Family

ID=52103660

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1356165A Pending FR3007653A3 (en) 2013-06-27 2013-06-27 USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS

Country Status (1)

Country Link
FR (1) FR3007653A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946508A4 (en) * 2019-03-25 2022-12-21 Mallinckrodt Pharmaceuticals Ireland Limited Gas delivery system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946508A4 (en) * 2019-03-25 2022-12-21 Mallinckrodt Pharmaceuticals Ireland Limited Gas delivery system

Similar Documents

Publication Publication Date Title
JP6518284B2 (en) Delivery of high concentration nitric oxide
Meiser et al. Desflurane compared with propofol for postoperative sedation in the intensive care unit
ES2202265T3 (en) MEDICINAL AEROSOL IN THE TREATMENT OR PREVENTION OF PAIN.
ES2554108T3 (en) Methods of treatment of necrotizing enterocolitis
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2020176134A5 (en)
WO2008095312A1 (en) Use of high dose concentrations of gaseous nitric oxide
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
Youssef et al. Airway management of an open penetrating neck injury
Egesa et al. Bubble Nasal Continuous Positive Airway Pressure (bNCPAP): An Effective Low‐Cost Intervention for Resource‐Constrained Settings
FR3007653A3 (en) USE OF NOBLE GAS FOR THE TREATMENT OF INTESTINAL REPERFUSION ISCHEMAS
Teah et al. Anaesthetic management in a patient requiring one lung ventilation during COVID-19 pandemic
Volpon et al. Methylene blue for refractory shock in polytraumatized patient: a case report
JP2021109860A (en) Molecular hydrogen-containing composition for promotion of postoperative recovery
Lindqvist et al. Minimal flow anaesthesia for short elective day case surgery; high vaporiser settings are needed but still cost-effective
JP6630115B2 (en) Pharmaceutical composition for reducing weight loss after extirpative surgery
RU2012116226A (en) Broncholytic agent based on prostaglandin
de Kubber et al. Non-traumatic splenic rupture in a patient on oral anticoagulation
Mattos et al. Chronic pain relief after the exposure of nitrous oxide during dental treatment: longitudinal retrospective study
Goudra et al. Anesthesia for ERCP
RU201845U1 (en) DEVICE OF AIR-OXYGEN-AIR MIXTURE DELIVERY CIRCUIT WITH NITROGEN OXIDE
Teah et al. Perioperative challenges in managing a morbidly obese patient with COVID-19 undergoing an elective tracheostomy
Fernandes et al. Effects of azathioprine on mucociliary clearance after bronchial section and anastomosis in a rat experimental model
Roy et al. Bilateral subglottic cysts in an infant treated with CO2 laser marsupialization
Balañá Corberó et al. Telematic adaptation to home mechanical ventilation in patients with amyotrophic lateral sclerosis